XML 25 R14.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Note 6 - Goodwill and Intangible Assets, Net | 9 Months Ended
--- | ---
Dec. 31, 2024
Notes to Financial Statements |
Goodwill and Intangible Assets Disclosure [Text Block] | Note 6. Goodwill and Intangible Assets, Net Finite-lived intangible assets consisted of the following:
|  | December 31, 2024 |  |  | March 31, 2024 |
|  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Net Carrying Amount |  |  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Net Carrying Amount |
Customer relationships |  | $ | 186,272 |  |  | $ | (112,475 | ) |  | $ | 73,797 |  |  | $ | 189,911 |  |  | $ | (104,528 | ) |  | $ | 85,383 |
Other intangibles |  |  | 60,356 |  |  |  | (35,972 | ) |  |  | 24,384 |  |  |  | 61,161 |  |  |  | (32,792 | ) |  |  | 28,369 |
Total finite-lived intangible assets |  | $ | 246,628 |  |  | $ | (148,447 | ) |  | $ | 98,181 |  |  | $ | 251,072 |  |  | $ | (137,320 | ) |  | $ | 113,752 |
Amortization expense for finite-lived intangible assets was as follows:
|  | Three Months Ended December 31, |  |  | Nine Months Ended December 31, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Amortization in cost of revenues |  | $ | 660 |  |  | $ | 1,883 |  |  | $ | 1,979 |  |  | $ | 5,367 |
Amortization in general and administrative |  |  | 3,731 |  |  |  | 6,092 |  |  |  | 11,023 |  |  |  | 17,013 |
Total amortization expense |  | $ | 4,391 |  |  | $ | 7,975 |  |  | $ | 13,002 |  |  | $ | 22,380 |
The decrease in amortization expense is attributable to impairment losses recorded during the fourth quarter of fiscal year 2024 related to intangible assets within our Clinical Genomics division. For the following fiscal years ending March 31, future amortization expense is estimated as follows, based on foreign currency exchange rates as of December 31, 2024:
Fiscal Year |  | Amortization Expense |
Remainder of 2025 |  | $ | 4,278 |
2026 |  |  | 16,566 |
2027 |  |  | 15,921 |
2028 |  |  | 15,349 |
2029 |  |  | 14,815 |
The change in the carrying amount of goodwill was as follows:
|  | Sterilization and Disinfection Control |  |  | Clinical Genomics |  |  | Biopharmaceutical Development |  |  | Calibration Solutions |  |  | Total |
March 31, 2024 |  | $ | 79,430 |  |  | $ | 16,940 |  |  | $ | 46,515 |  |  | $ | 37,211 |  |  |  | 180,096 |
Effect of foreign currency translation |  |  | (1,994 | ) |  |  | (71 | ) |  |  | (849 | ) |  |  | (30 | ) |  |  | (2,944 | )
December 31, 2024 |  | $ | 77,436 |  |  | $ | 16,869 |  |  | $ | 45,666 |  |  | $ | 37,181 |  |  | $ | 177,152 |

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContent Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration